294 related articles for article (PubMed ID: 22270929)
1. Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials.
Jacquin JP; Jones S; Magné N; Chapelle C; Ellis P; Janni W; Mavroudis D; Martín M; Laporte S
Breast Cancer Res Treat; 2012 Aug; 134(3):903-13. PubMed ID: 22270929
[TBL] [Abstract][Full Text] [Related]
2. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
De Laurentiis M; Cancello G; D'Agostino D; Giuliano M; Giordano A; Montagna E; Lauria R; Forestieri V; Esposito A; Silvestro L; Pennacchio R; Criscitiello C; Montanino A; Limite G; Bianco AR; De Placido S
J Clin Oncol; 2008 Jan; 26(1):44-53. PubMed ID: 18165639
[TBL] [Abstract][Full Text] [Related]
3. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
4. Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials.
Shao N; Wang S; Yao C; Xu X; Zhang Y; Zhang Y; Lin Y
Breast; 2012 Jun; 21(3):389-93. PubMed ID: 22542064
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
6. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
Gennari A; Sormani MP; Pronzato P; Puntoni M; Colozza M; Pfeffer U; Bruzzi P
J Natl Cancer Inst; 2008 Jan; 100(1):14-20. PubMed ID: 18159072
[TBL] [Abstract][Full Text] [Related]
7. Taxanes for adjuvant treatment of early breast cancer.
Willson ML; Burke L; Ferguson T; Ghersi D; Nowak AK; Wilcken N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD004421. PubMed ID: 31476253
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials.
Caparica R; Bruzzone M; Poggio F; Ceppi M; de Azambuja E; Lambertini M
Breast Cancer Res Treat; 2019 Feb; 174(1):27-37. PubMed ID: 30465156
[TBL] [Abstract][Full Text] [Related]
9. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
[TBL] [Abstract][Full Text] [Related]
10. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients.
Bria E; Nistico C; Cuppone F; Carlini P; Ciccarese M; Milella M; Natoli G; Terzoli E; Cognetti F; Giannarelli D
Cancer; 2006 Jun; 106(11):2337-44. PubMed ID: 16649217
[TBL] [Abstract][Full Text] [Related]
11. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
[TBL] [Abstract][Full Text] [Related]
12. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Hoon SN; Lau PK; White AM; Bulsara MK; Banks PD; Redfern AD
Cochrane Database Syst Rev; 2021 May; 5(5):CD011220. PubMed ID: 34037241
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.
Andre F; Broglio K; Roche H; Martin M; Mackey JR; Penault-Llorca F; Hortobagyi GN; Pusztai L
J Clin Oncol; 2008 Jun; 26(16):2636-43. PubMed ID: 18509176
[TBL] [Abstract][Full Text] [Related]
15. Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
Yardley DA; Hart L; Waterhouse D; Whorf R; Drosick DR; Murphy P; Badarinath S; Daniel BR; Childs BH; Burris H
Breast Cancer Res Treat; 2013 Dec; 142(3):655-65. PubMed ID: 24253810
[TBL] [Abstract][Full Text] [Related]
16. Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.
Poggio F; Ceppi M; Lambertini M; Bruzzi P; Ugolini D; Bighin C; Levaggi A; Giraudi S; D'Alonzo A; Vaglica M; Blondeaux E; Sertoli MR; Pronzato P; Del Mastro L
Breast; 2017 Jun; 33():104-108. PubMed ID: 28360014
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
